Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arcutis Biotherapeutics Announces Long-Term Results From INTEGUMENT-OLE Study, Showing Durable Efficacy And Favorable Safety Of Roflumilast Cream 0.05% In Treating Mild To Moderate AD In Children; 71.9% Achieved EASI-75 After 56 Weeks; Plans sNDA Submission To FDA In Q1 2025

Author: Benzinga Newsdesk | August 28, 2024 08:07am

Posted In: ARQT